These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 32334059

  • 1. The importance of differentiating between mycosis fungoides with CD30-positive large cell transformation and mycosis fungoides with coexistent primary cutaneous anaplastic large cell lymphoma.
    Gao C, McCormack CJ, van der Weyden C, Twigger R, Buelens O, Lade S, Khoo C, Campbell BA, Goh M, McKelvie P, Prince HM.
    J Am Acad Dermatol; 2021 Jan; 84(1):185-187. PubMed ID: 32334059
    [No Abstract] [Full Text] [Related]

  • 2. Disseminated CD8-positive, CD30-positive cutaneous lymphoproliferative eruption with overlapping features of mycosis fungoides and primary cutaneous anaplastic large cell lymphoma following remote solitary lesional presentation.
    Davick JJ, Mutgi KAJ, Wanat KA, Link BK, Liu V.
    J Cutan Pathol; 2017 Aug; 44(8):703-712. PubMed ID: 28497585
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Is immunohistochemical expression of GATA3 helpful in the differential diagnosis of transformed mycosis fungoides and primary cutaneous CD30-positive T cell lymphoproliferative disorders?
    Collins K, Gu J, Aung PP, Nagarajan P, Curry JL, Huen A, Ivan D, Prieto VG, Tetzlaff MT, Duvic M, Miranda RN, Vega F, Torres-Cabala CA.
    Virchows Arch; 2021 Aug; 479(2):377-383. PubMed ID: 33604757
    [Abstract] [Full Text] [Related]

  • 6. Primary cutaneous anaplastic large cell lymphoma.
    Brown RA, Fernandez-Pol S, Kim J.
    J Cutan Pathol; 2017 Jun; 44(6):570-577. PubMed ID: 28342276
    [Abstract] [Full Text] [Related]

  • 7. A case of mycosis fungoides after CD30 positive anaplastic large cell lymphoma.
    Lee MW, Chi DH, Choi JH, Sung KJ, Moon KC, Koh JK.
    J Dermatol; 2000 Jul; 27(7):458-61. PubMed ID: 10935344
    [Abstract] [Full Text] [Related]

  • 8. Large-cell transformation of mycosis fungoides-differential diagnosis with implications for clinical management: a consensus statement of the US Cutaneous Lymphoma Consortium.
    Kadin ME, Hughey LC, Wood GS.
    J Am Acad Dermatol; 2014 Feb; 70(2):374-6. PubMed ID: 24438952
    [No Abstract] [Full Text] [Related]

  • 9. Differential molecular programs of cutaneous anaplastic large cell lymphoma and CD30-positive transformed mycosis fungoides.
    Lai P, Liu F, Liu X, Sun J, Wang Y.
    Front Immunol; 2023 Feb; 14():1270365. PubMed ID: 37790936
    [Abstract] [Full Text] [Related]

  • 10. CD30-positive anaplastic large-cell lymphoma associated with mycosis fungoides after treatment with dupilumab.
    Saad S, Ram-Wolff C, De Masson A, Jachiet M, Battistella M, Vignon-Pennamen MD, Rivet J, Michel L, Mourah S, Bagot M, Dobos G.
    Eur J Dermatol; 2022 Jul 01; 32(4):536-537. PubMed ID: 36301751
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Clusterin expression correlates with stage and presence of large cells in mycosis fungoides.
    Chandra P, Plaza JA, Zuo Z, Diwan AH, Koeppen H, Duvic M, Medeiros LJ, Prieto VG.
    Am J Clin Pathol; 2009 Apr 01; 131(4):511-5. PubMed ID: 19289586
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Utility of CD30, Ki-67, and p53 in assisting with the diagnosis of mycosis fungoides with large cell transformation.
    Raghavan SS, Hong EK, Kim YH, Kim J.
    J Cutan Pathol; 2019 Jan 01; 46(1):33-43. PubMed ID: 30328119
    [Abstract] [Full Text] [Related]

  • 17. The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 cases.
    Beylot-Barry M, Vergier B, Masquelier B, Bagot M, Joly P, Souteyrand P, Vaillant L, Avril MF, Franck N, Fraitag S, Delaunay M, Laroche L, Estève E, Courville P, Dechelotte P, Beylot C, De Mascarel A, Wechsler J, Merlio JP.
    Am J Surg Pathol; 1999 Oct 01; 23(10):1208-16. PubMed ID: 10524521
    [Abstract] [Full Text] [Related]

  • 18. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis.
    Kim YH, Prince HM, Whittaker S, Horwitz SM, Duvic M, Bechter O, Sanches JA, Stadler R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Eradat H, Pinter-Brown LC, Ortiz-Romero PL, Akilov OE, Trotman J, Taylor K, Weichenthal M, Walewski J, Fisher D, McNeeley M, Gru AA, Brown L, Palanca-Wessels MC, Lisano J, Onsum M, Bunn V, Little M, Trepicchio WL, Dummer R.
    Eur J Cancer; 2021 May 01; 148():411-421. PubMed ID: 33794441
    [Abstract] [Full Text] [Related]

  • 19. Impressive response of CD30-negative, treatment-refractory mycosis fungoides to brentuximab vedotin.
    Goyal A, Hordinsky M, Lazaryan A.
    Dermatol Ther; 2019 Mar 01; 32(2):e12835. PubMed ID: 30659762
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.